Literature DB >> 24900621

Discovery of Pyridyl Bis(oxy)dibenzimidamide Derivatives as Selective Matriptase Inhibitors.

Rajeev Goswami1, Subhendu Mukherjee1, Gerd Wohlfahrt2, Chakshusmathi Ghadiyaram1, Jwala Nagaraj1, Beeram Ravi Chandra1, Ramesh K Sistla1, Leena K Satyam1, Dodheri S Samiulla1, Anu Moilanen3, Hosahalli S Subramanya1, Murali Ramachandra1.   

Abstract

Matriptase belongs to trypsin-like serine proteases involved in matrix remodeling/degradation, growth regulation, survival, motility, and cell morphogenesis. Herein, we report a structure-based approach, which led to the discovery of sulfonamide and amide derivatives of pyridyl bis(oxy)benzamidine as potent and selective matriptase inhibitors. Co-crystal structures of selected compounds in complex with matriptase supported compound designing. Additionally, WaterMap analyses indicated the possibility of occupying a distinct pocket within the catalytic domain, exploration of which resulted in >100-fold improvement in potency. Co-crystal structure of 10 with matriptase revealed critical interactions leading to potent target inhibition and selectivity against other serine proteases.

Entities:  

Keywords:  Matriptase; SAR; cancer; crystal structure; pyridyl dibenzimidamide

Year:  2013        PMID: 24900621      PMCID: PMC4027570          DOI: 10.1021/ml400213v

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  25 in total

Review 1.  Type II transmembrane serine proteases. Insights into an emerging class of cell surface proteolytic enzymes.

Authors:  J D Hooper; J A Clements; J P Quigley; T M Antalis
Journal:  J Biol Chem       Date:  2001-01-12       Impact factor: 5.157

2.  Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase.

Authors:  I J Enyedy; S L Lee; A H Kuo; R B Dickson; C Y Lin; S Wang
Journal:  J Med Chem       Date:  2001-04-26       Impact factor: 7.446

Review 3.  Matrix metalloproteinases and tumor metastasis.

Authors:  Elena I Deryugina; James P Quigley
Journal:  Cancer Metastasis Rev       Date:  2006-03       Impact factor: 9.264

4.  Design and synthesis of potent, selective inhibitors of matriptase.

Authors:  Eloïc Colombo; Antoine Désilets; Dominic Duchêne; Félix Chagnon; Rafael Najmanovich; Richard Leduc; Eric Marsault
Journal:  ACS Med Chem Lett       Date:  2012-04-11       Impact factor: 4.345

5.  Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis.

Authors:  Karin List; Christian C Haudenschild; Roman Szabo; WanJun Chen; Sharon M Wahl; William Swaim; Lars H Engelholm; Niels Behrendt; Thomas H Bugge
Journal:  Oncogene       Date:  2002-05-23       Impact factor: 9.867

6.  Secondary amides of sulfonylated 3-amidinophenylalanine. New potent and selective inhibitors of matriptase.

Authors:  Torsten Steinmetzer; Andrea Schweinitz; Anne Stürzebecher; Daniel Dönnecke; Kerstin Uhland; Oliver Schuster; Peter Steinmetzer; Friedemann Müller; Rainer Friedrich; Manuel E Than; Wolfram Bode; Jörg Stürzebecher
Journal:  J Med Chem       Date:  2006-07-13       Impact factor: 7.446

7.  Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease.

Authors:  S L Lee; R B Dickson; C Y Lin
Journal:  J Biol Chem       Date:  2000-11-24       Impact factor: 5.157

8.  Inhibition of the invasion capacity of carcinoma cells by WX-UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator system.

Authors:  Suna Ertongur; Stephan Lang; Brigitte Mack; Katja Wosikowski; Bernd Muehlenweg; Olivier Gires
Journal:  Int J Cancer       Date:  2004-07-20       Impact factor: 7.396

9.  Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase.

Authors:  Mika Suzuki; Hiroshi Kobayashi; Naohiro Kanayama; Yasushi Saga; Mitsuaki Suzuki; Chen-Yong Lin; Robert B Dickson; Toshihiko Terao
Journal:  J Biol Chem       Date:  2004-01-27       Impact factor: 5.157

10.  Matriptase, HAT, and TMPRSS2 activate the hemagglutinin of H9N2 influenza A viruses.

Authors:  Joanna Baron; Carolin Tarnow; Deborah Mayoli-Nüssle; Eva Schilling; Daniela Meyer; Maya Hammami; Folker Schwalm; Torsten Steinmetzer; Yi Guan; Wolfgang Garten; Hans-Dieter Klenk; Eva Böttcher-Friebertshäuser
Journal:  J Virol       Date:  2012-11-28       Impact factor: 5.103

View more
  5 in total

1.  Piperidine carbamate peptidomimetic inhibitors of the serine proteases HGFA, matriptase and hepsin.

Authors:  Vishnu C Damalanka; Scott A Wildman; James W Janetka
Journal:  Medchemcomm       Date:  2019-07-18       Impact factor: 3.597

2.  Deregulated hepsin protease activity confers oncogenicity by concomitantly augmenting HGF/MET signalling and disrupting epithelial cohesion.

Authors:  T A Tervonen; D Belitškin; S M Pant; J I Englund; E Marques; H Ala-Hongisto; L Nevalaita; H Sihto; P Heikkilä; M Leidenius; K Hewitson; M Ramachandra; A Moilanen; H Joensuu; P E Kovanen; A Poso; J Klefström
Journal:  Oncogene       Date:  2015-07-13       Impact factor: 9.867

3.  Structure-Activity Studies with Bis-Amidines That Potentiate Gram-Positive Specific Antibiotics against Gram-Negative Pathogens.

Authors:  Charlotte M J Wesseling; Cornelis J Slingerland; Shanice Veraar; Samantha Lok; Nathaniel I Martin
Journal:  ACS Infect Dis       Date:  2021-11-12       Impact factor: 5.084

4.  Matriptase Induction of Metalloproteinase-Dependent Aggrecanolysis In Vitro and In Vivo: Promotion of Osteoarthritic Cartilage Damage by Multiple Mechanisms.

Authors:  David J Wilkinson; Hui Wang; Angela Habgood; Heather K Lamb; Paul Thompson; Alastair R Hawkins; Antoine Désilets; Richard Leduc; Torsten Steinmetzer; Maya Hammami; Melody S Lee; Charles S Craik; Sharon Watson; Hua Lin; Jennifer M Milner; Andrew D Rowan
Journal:  Arthritis Rheumatol       Date:  2017-07-05       Impact factor: 15.483

5.  3-Cl-AHPC inhibits pro-HGF maturation by inducing matriptase/HAI-1 complex formation.

Authors:  Fang Ye; Shuang Chen; Xingxing Liu; Xiaohong Ye; Keqi Wang; Zhiping Zeng; Ying Su; Xiao-Kun Zhang; Hu Zhou
Journal:  J Cell Mol Med       Date:  2018-10-28       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.